KR102228055B1 - 종양의 치료 또는 예방을 위한 병용 요법 - Google Patents

종양의 치료 또는 예방을 위한 병용 요법 Download PDF

Info

Publication number
KR102228055B1
KR102228055B1 KR1020197031149A KR20197031149A KR102228055B1 KR 102228055 B1 KR102228055 B1 KR 102228055B1 KR 1020197031149 A KR1020197031149 A KR 1020197031149A KR 20197031149 A KR20197031149 A KR 20197031149A KR 102228055 B1 KR102228055 B1 KR 102228055B1
Authority
KR
South Korea
Prior art keywords
compound
epoxytiglian
tumor
immune checkpoint
checkpoint inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197031149A
Other languages
English (en)
Korean (ko)
Other versions
KR20190126431A (ko
Inventor
폴 워렌 레델
제이슨 킹슬리 컬렌
글렌 매튜 보일
피터 고든 파슨스
빅토리아 앤 고든
Original Assignee
큐바이오틱스 피티와이 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017901027A external-priority patent/AU2017901027A0/en
Application filed by 큐바이오틱스 피티와이 리미티드 filed Critical 큐바이오틱스 피티와이 리미티드
Publication of KR20190126431A publication Critical patent/KR20190126431A/ko
Application granted granted Critical
Publication of KR102228055B1 publication Critical patent/KR102228055B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020197031149A 2017-03-23 2018-03-23 종양의 치료 또는 예방을 위한 병용 요법 Active KR102228055B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2017901027 2017-03-23
AU2017901027A AU2017901027A0 (en) 2017-03-23 Combination Therapy
PCT/AU2018/050277 WO2018170559A1 (en) 2017-03-23 2018-03-23 Combination therapy for the treatment or prevention of tumours

Publications (2)

Publication Number Publication Date
KR20190126431A KR20190126431A (ko) 2019-11-11
KR102228055B1 true KR102228055B1 (ko) 2021-03-16

Family

ID=63583892

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197031149A Active KR102228055B1 (ko) 2017-03-23 2018-03-23 종양의 치료 또는 예방을 위한 병용 요법

Country Status (27)

Country Link
US (1) US11213506B2 (cg-RX-API-DMAC7.html)
EP (1) EP3600281B1 (cg-RX-API-DMAC7.html)
JP (1) JP6905075B2 (cg-RX-API-DMAC7.html)
KR (1) KR102228055B1 (cg-RX-API-DMAC7.html)
CN (1) CN110461324A (cg-RX-API-DMAC7.html)
AU (1) AU2018238202C1 (cg-RX-API-DMAC7.html)
CA (1) CA3056685C (cg-RX-API-DMAC7.html)
DK (1) DK3600281T3 (cg-RX-API-DMAC7.html)
EA (1) EA201992220A1 (cg-RX-API-DMAC7.html)
ES (1) ES2953575T3 (cg-RX-API-DMAC7.html)
FI (1) FI3600281T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20230936T1 (cg-RX-API-DMAC7.html)
HU (1) HUE063299T2 (cg-RX-API-DMAC7.html)
IL (1) IL269522B2 (cg-RX-API-DMAC7.html)
LT (1) LT3600281T (cg-RX-API-DMAC7.html)
MX (1) MX391826B (cg-RX-API-DMAC7.html)
MY (1) MY197427A (cg-RX-API-DMAC7.html)
PH (1) PH12019502132A1 (cg-RX-API-DMAC7.html)
PL (1) PL3600281T3 (cg-RX-API-DMAC7.html)
PT (1) PT3600281T (cg-RX-API-DMAC7.html)
RS (1) RS64472B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201907891XA (cg-RX-API-DMAC7.html)
SI (1) SI3600281T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202300272T1 (cg-RX-API-DMAC7.html)
UA (1) UA125614C2 (cg-RX-API-DMAC7.html)
WO (1) WO2018170559A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201906001B (cg-RX-API-DMAC7.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1971588T3 (da) * 2005-12-23 2012-10-22 Qbiotics Ltd Tiglien-3-onderivater
KR102160389B1 (ko) 2013-08-05 2020-09-28 트위스트 바이오사이언스 코포레이션 드 노보 합성된 유전자 라이브러리
CA2975852A1 (en) 2015-02-04 2016-08-11 Twist Bioscience Corporation Methods and devices for de novo oligonucleic acid assembly
WO2016172377A1 (en) 2015-04-21 2016-10-27 Twist Bioscience Corporation Devices and methods for oligonucleic acid library synthesis
KR20180050411A (ko) 2015-09-18 2018-05-14 트위스트 바이오사이언스 코포레이션 올리고핵산 변이체 라이브러리 및 그의 합성
WO2017053450A1 (en) 2015-09-22 2017-03-30 Twist Bioscience Corporation Flexible substrates for nucleic acid synthesis
EP4664304A3 (en) 2016-09-21 2026-01-21 Atlas Data Storage, Inc. Nucleic acid based data storage
WO2018156792A1 (en) 2017-02-22 2018-08-30 Twist Bioscience Corporation Nucleic acid based data storage
IL271205B2 (en) 2017-06-12 2025-02-01 Twist Bioscience Corp Methods for assembling continuous nucleic acids
WO2018231864A1 (en) 2017-06-12 2018-12-20 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
CN111566125A (zh) 2017-09-11 2020-08-21 特韦斯特生物科学公司 Gpcr结合蛋白及其合成
CN111565834B (zh) 2017-10-20 2022-08-26 特韦斯特生物科学公司 用于多核苷酸合成的加热的纳米孔
IL312616B2 (en) 2018-01-04 2025-08-01 Twist Bioscience Corp Dna-based digital information storage
EP3814497A4 (en) 2018-05-18 2022-03-02 Twist Bioscience Corporation POLYNUCLEOTIDES, REAGENTS AND METHODS FOR NUCLEIC ACID HYBRIDIZATION
EP3902816A4 (en) 2018-12-26 2022-09-14 Twist Bioscience Corporation HIGH-PRECISION DE NOVO POLYNUCLEOTIDE SYNTHESIS
CA3131689A1 (en) 2019-02-26 2020-09-03 Twist Bioscience Corporation Variant nucleic acid libraries for glp1 receptor
KR20210144698A (ko) 2019-02-26 2021-11-30 트위스트 바이오사이언스 코포레이션 항체 최적화를 위한 변이 핵산 라이브러리
PL3952858T3 (pl) * 2019-04-12 2026-03-30 QBiotics Pty Ltd Sposób leczenia guzów
BR112021024716A2 (pt) * 2019-06-19 2022-02-08 QBiotics Pty Ltd Ruptura de biofilme
EP3987019A4 (en) 2019-06-21 2023-04-19 Twist Bioscience Corporation Barcode-based nucleic acid sequence assembly
CN115023440B (zh) 2019-09-23 2025-09-12 特韦斯特生物科学公司 结合CD3ε的抗体
US12091777B2 (en) 2019-09-23 2024-09-17 Twist Bioscience Corporation Variant nucleic acid libraries for CRTH2
AU2020400030B2 (en) 2019-12-09 2026-05-21 Twist Bioscience Corporation Variant nucleic acid libraries for adenosine receptors
WO2022159620A1 (en) 2021-01-21 2022-07-28 Twist Bioscience Corporation Methods and compositions relating to adenosine receptors
KR102774792B1 (ko) 2021-05-06 2025-03-05 한국과학기술연구원 가시광선에 의해 활성화되는 항암 면역치료용 나노입자 및 이의 용도
CN118451065A (zh) * 2021-12-21 2024-08-06 Q生物股份有限公司 结晶中间体
JP2025505797A (ja) * 2022-02-17 2025-02-28 キューバイオティクス プロプライアタリー リミティド 併用療法
EP4638430A4 (en) * 2022-12-21 2026-07-01 QBiotics Pty Ltd CRYSTALLINE FORMS AND THEIR PRODUCTION PROCESSES

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007070985A1 (en) 2005-12-23 2007-06-28 Qbiotics Limited Tiglien-3-one derivatives
CN104926758A (zh) 2015-05-22 2015-09-23 南京泽朗医药科技有限公司 斑籽素的制备方法及其在抗白血病药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007009055A2 (en) * 2005-07-13 2007-01-18 Salvia Sciences, Inc. Ester prodrugs of prostratin and related phorbol compounds
PT2986615T (pt) * 2013-04-18 2019-03-22 Qbiotics Ltd Métodos e composições para a cicatrização de feridas
JP6501413B2 (ja) * 2014-03-07 2019-04-17 国立大学法人京都大学 細胞培養用組成物
ES2833425T3 (es) 2014-07-16 2021-06-15 Roussy Inst Gustave Combinación de virus oncolítico con moduladores de punto de control inmunitario
CA2964155A1 (en) 2014-10-10 2016-04-14 Idera Pharmaceuticals, Inc. Treatment of cancer using tlr9 agonist with checkpoint inhibitors
AR105592A1 (es) * 2015-08-03 2017-10-18 Quadriga Biosciences Inc b-AMINOÁCIDOS b-SUSTITUIDOS Y ANÁLOGOS COMO AGENTES QUIMIOTERAPÉUTICOS Y USOS DE LOS MISMOS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007070985A1 (en) 2005-12-23 2007-06-28 Qbiotics Limited Tiglien-3-one derivatives
CN104926758A (zh) 2015-05-22 2015-09-23 南京泽朗医药科技有限公司 斑籽素的制备方法及其在抗白血病药物中的应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PLOS ONE, 9(10), e108887, 2014.

Also Published As

Publication number Publication date
PH12019502132A1 (en) 2020-07-06
US11213506B2 (en) 2022-01-04
JP6905075B2 (ja) 2021-07-21
AU2018238202B2 (en) 2024-03-28
SI3600281T1 (sl) 2023-10-30
AU2018238202A8 (en) 2024-03-28
SG11201907891XA (en) 2019-09-27
US20200030279A1 (en) 2020-01-30
PT3600281T (pt) 2023-09-04
EA201992220A1 (ru) 2020-02-11
NZ756754A (en) 2024-02-23
MX391826B (es) 2025-03-21
IL269522A (cg-RX-API-DMAC7.html) 2019-11-28
RS64472B1 (sr) 2023-09-29
WO2018170559A1 (en) 2018-09-27
ZA201906001B (en) 2023-12-20
LT3600281T (lt) 2023-09-11
MY197427A (en) 2023-06-16
DK3600281T3 (da) 2023-08-14
IL269522B1 (en) 2024-01-01
SMT202300272T1 (it) 2023-09-06
HUE063299T2 (hu) 2024-01-28
UA125614C2 (uk) 2022-05-04
ES2953575T3 (es) 2023-11-14
BR112019019748A2 (pt) 2020-04-14
EP3600281A4 (en) 2020-03-18
KR20190126431A (ko) 2019-11-11
AU2018238202A1 (en) 2019-09-19
CA3056685A1 (en) 2018-09-27
AU2018238202C1 (en) 2025-06-05
JP2020511512A (ja) 2020-04-16
HRP20230936T1 (hr) 2023-11-24
CA3056685C (en) 2024-01-16
MX2019011221A (es) 2019-11-01
EP3600281B1 (en) 2023-05-31
FI3600281T3 (fi) 2023-08-24
PL3600281T3 (pl) 2023-09-11
IL269522B2 (en) 2024-05-01
CN110461324A (zh) 2019-11-15
EP3600281A1 (en) 2020-02-05

Similar Documents

Publication Publication Date Title
JP6905075B2 (ja) 腫瘍の治療または予防のための併用療法
TW201842921A (zh) 治療性rna
US10130590B2 (en) Methods of treating cancer with atovaquone-related compounds
US12226391B2 (en) Method of treating tumours
Wang et al. A chemical conjugation of JQ‐1 and a TLR7 agonist induces tumoricidal effects in a murine model of melanoma via enhanced immunomodulation
Zuo et al. A novel oral TLR7 agonist orchestrates immune response and synergizes with PD-L1 blockade via type I IFN pathway in lung cancer
AU2019398198B2 (en) CXCR7 inhibitors for the treatment of cancer
TWI614029B (zh) 新穎醫藥組成物及其用途
JP7044803B2 (ja) 癌の治療のための化合物、組成物およびその使用
EA044756B1 (ru) Комбинированная терапия для лечения или предупреждения опухолей
HK40014624B (en) Combination therapy for the treatment or prevention of tumours
HK40014624A (en) Combination therapy for the treatment or prevention of tumours
BR112019019748B1 (pt) Usos de um composto de epóxitigliano ou um sal farmaceuticamente aceitável do mesmo, usos de um inibidor do ponto de verificação imunológico e kit
WO2025217270A1 (en) METHODS OF TREATMENT USING TGFb-RECEPTOR 1 INHIBITION AND LTBR AGONISM
HK40060616B (en) Method of treating tumours
HK40060616A (en) Method of treating tumours

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
A302 Request for accelerated examination
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 5